The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $369.88

Today's change+2.92 +0.80%
Updated January 16 12:48 PM EST. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $369.88

Today's change+2.92 +0.80%
Updated January 16 12:48 PM EST. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc up (U.S.)$2.92

Regeneron Pharmaceuticals Inc is up today by (U.S.)$2.92 or 0.80% to (U.S.)$369.88. Over the last five days, shares have gained 0.33%, but are currently unchanged over the last 52 weeks. This lagged the 22.70% return in the S&P 500.

Key company metrics

  • Open(U.S.) $368.92
  • Previous close(U.S.) $366.96
  • High(U.S.) $374.81
  • Low(U.S.) $367.35
  • Bid / Ask(U.S.) $369.60 / (U.S.) $370.19
  • YTD % change-1.62%
  • Volume532,068
  • Average volume (10-day)766,881
  • Average volume (1-month)722,270
  • Average volume (3-month)836,936
  • 52-week range(U.S.) $340.09 to (U.S.) $543.55
  • Beta1.52
  • Trailing P/E33.60×
  • P/E 1 year forward23.46×
  • Forward PEG1.34×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $11.01
Updated January 16 12:48 PM EST. Delayed by at least 15 minutes.
S&P TSX0.27%Sector:HealthcareIndustry:Biotechnology

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue1,5011,4701,3191,227
Total other revenue--------
Total revenue1,5011,4701,3191,227
Gross profit1,3961,3671,2351,152
Total cost of revenue1041038475
Total operating expense941920888880
Selling / general / administrative307307297326
Research & development530510507479
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income560550431347
Interest income (expense), net non-operating-6-5-8--
Gain (loss) on sale of assets--------
Other--------
Income before tax566526432342
Income after tax388388249253
Income tax, total17713818388
Net income388388249253
Total adjustments to net income--------
Net income before extra. items388388249253
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items388388249253
Inc. avail. to common incl. extra. items388388249253
Diluted net income388388249253
Dilution adjustment00--0
Diluted weighted average shares117116115116
Diluted EPS excluding extraordinary itemsvalue per share3.323.342.162.19
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share3.323.342.162.19